We are the first publicly-traded biotech or pharmaceutical company to take the form of a public benefit corporation. Our public benefit purpose is to provide a brighter future for patients through the development of novel pharmaceutical therapies; and technologies that expand the availability of transplantable organs. United Therapeutics (Nasdaq: UTHR ) seeks to travel down the corridors of indifference to develop treatments for rare, deadly diseases. We were founded in 1996 by a family seeking a cure for their daughter’s pulmonary arterial hypertension ( PAH ). Today, we have six FDA-approved therapies that treat PAH, pulmonary hypertension associated with interstitial lung disease ( PH-ILD ) and neuroblastoma, a rare pediatric cancer. Our near-term pipeline seeks to develop additional therapies for PAH and pulmonary fibrosis ( PF ). The cure for end-stage life-threatening diseases like PAH, PH-ILD, PF, and many others is an organ transplant, but only a small percentage of donated organs are available to address the vast need. For this reason, we are working to create manufactured organs to address the shortage of kidneys, hearts, lungs, and livers available for transplant. We believe an unlimited supply of tolerable, transplantable organs will eliminate the transplant waiting list and cure end-stage organ diseases for which transplant is not currently an option. Millions worldwide are living with chronic kidney disease or diabetes. Management and maintenance therapies are ongoing, expensive, and often undermine the person’s quality of life. Their only hope for a cure is an kidney transplant. Unfortunately, the shortage of available kidneys causes patients to spend an average of 5 or more years on the waitlist, and many die before receiving surgery. At IVIVA, we are working to transform the status quo by developing fully implantable bioartificial kidneys. Our goal is to develop a cure that can allows patients with kidney dysfunction to lead a normal life There has never been a more exciting time to join IVIVA, a United Therapeutics company. This position offers someone the opportunity of a lifetime – to see a product into something real, an opportunity to create a human kidney equivalent and save lives on a scale before unknown. This position is seeking a endothelial and/or epithelial cell biologist and enthusiast to advance the maturity and function of iPS derived renal cells in 2D and 3D systems. This position plans, conducts, and supports experiments to develop, manufacture, and evaluate cell-based therapeutics for the treatment of end-stage renal disease. Does this sound like you? Apply below and we look forward to chatting with you!
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Mid Level
Number of Employees
1,001-5,000 employees